During the corresponding time, Deciphera Pharmaceuticals Inc recorded a revenue increase by 34.55 % year on year, sequentially revenue fell by -6.82 %. While revenue at the Deciphera Pharmaceuticals Inc 's corporate clients
In a significant development within the oncology pharmaceutical sector, Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), has announced that the results from its MOTION pivotal Phase 3 study of vimseltinib in patients with tenosynovial giant cell tumor (TGCT) will be prominently featured at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is scheduled to take place in Chicago, Illinois.Deciphera Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of new medicines aimed at improving the quality of life for cancer patients. The company’s recent announcement underscores the potential impact of vimseltinib as a...
WALTHAM, Mass. - Deciphera Pharmaceuticals, a renowned biopharmaceutical company dedicated to the development of groundbreaking cancer treatments, has recently announced the release of long-term findings from the INTRIGUE Phase 3 clinical study. These results shed light on the efficacy of QINLOCK (ripretinib) in comparison to sunitinib for patients with advanced gastrointestinal stromal tumor (GIST) who have undergone prior treatment with imatinib. The presentation of these findings took place at the esteemed 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, marking a significant stride forward in the pursuit of improved treatments for GIST patients.GIST is a type of cancer that ...
In a significant development, GENESIS Pharma, a renowned regional biopharmaceutical company operating in Europe, has recently entered into an exclusive distribution agreement with Deciphera Pharmaceuticals, Inc. The agreement involves the marketing of RIPRETINIB, a groundbreaking medication designed to improve the lives of cancer patients, across 14 markets in Central and Eastern Europe. This collaboration holds vast potential for both companies and has far-reaching implications for GENESIS Pharma s expansion and reputation in the region.Facts:1. GENESIS Pharma, a leading regional biopharmaceutical company operating in Europe, has joined forces with Deciphera Pharmaceuticals, Inc., a company dedicated to dis...
Massachusetts-based biopharmaceutical company, Deciphera Pharmaceuticals, recently unveiled its strategic outlook for 2024 and disclosed preliminary unaudited fourth quarter and full year 2023 revenue figures. These announcements not only shed light on the company s progress but also underline its commitment to developing and commercializing groundbreaking medicines that can significantly improve the lives of cancer patients.Throughout 2023, Deciphera Pharmaceuticals achieved significant milestones, showcasing its ability to deliver on its mission. The company s focus on discovering novel therapies for cancer treatment has sparked considerable interest within the medical community and among investors alike. ...
Deciphera Pharmaceuticals, a formidable player in the biopharmaceutical domain, continues to leave an indelible impact in the global fight against cancer. It recently announced a significant accomplishment - Nature Medicine s publication of the results derived from a key ctDNA (circulating tumor DNA) analysis from its pivotal INTRIGUE Phase 3 study. This critical research focused on examining the effectiveness of QINLOCK (ripretinib) in managing Gastrointestinal Stromal Tumors (GIST) in patients presenting mutations in KIT exon 11 and 17/18, who had only been previously treated with imatinib.Deciphera s mission and principal thrust has always been discovering, developing, and commercializing novel and revolu...
Sources:
Deciphera Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Deciphera Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Deciphera Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
